A major problem with the current treatment options for autoimmunity is the unintended immune suppression. Most current immuno-modulatory therapies involve monoclonal antibodies, which can create multiple complications. Antibodies notoriously cross react with unintended targets and are very large molecules that must clear renal systems. Due to the large size of monoclonal antibodies, the treatment itself can become immunogenic, i.e. the monoclonal antibody causes immune attack on itself. Op-T does not use monoclonal antibodies. The company has developed small peptides that modulate but do not eliminate inflammatory cells. This approach constitutes a new way to target a highly inflammatory pathway.